(Q68512926)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3420036%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

title

Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3420036%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

Efficacy and advantages in the use of low doses of anandron and estrogen combination in the treatment of prostate cancer (English)

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

9 January 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3420036

9 January 2023

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

9 January 2023

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

9 January 2023

author name string

B. R. Rao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3420036

9 January 2023

A. A. Geldof

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3420036

9 January 2023

C. L. van der Wilt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3420036

9 January 2023

H. J. de Voogt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3420036

9 January 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=3420036

9 January 2023

publication date

1 January 1988

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3420036%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

25 September 2019

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.2990130108

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

https://onlinelibrary.wiley.com/doi/full/10.1002/pros.2990130108

9 January 2023

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

9 January 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3420036%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3420036%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3420036%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

page(s)

69-78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3420036%20AND%20SRC:MED&resulttype=core&format=json

Carcinoma of the prostate in sex chromatin positive (XXX/XY) Klinefelter's syndrome

25 September 2019

cites work

3

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens

9 January 2023

4

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

Biological significance of measurable androgen levels in the rat ventral prostate following castration

9 January 2023

7

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

The pure antiandrogen ru 23908 (anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review

9 January 2023

9

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

Effects of androgenic steroids on erythropoiesis

9 January 2023

12

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate

9 January 2023

14

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H)

9 January 2023

15

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma

9 January 2023

19

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study

9 January 2023

21

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer

9 January 2023

22

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

Concentration and cellular distribution of androgen receptor in human prostatic neoplasia: can estrogen treatment increase androgen receptor content?

9 January 2023

24

1 reference

https://api.crossref.org/works/10.1002/PROS.2990130108

9 January 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3420036%20AND%20SRC:MED&resulttype=core&format=json

25 September 2019

1 reference